Roche Seeks $6.8 Billion Win on Heart Pill Where Pfizer Failed - Businessweek: Roche decided to continue with dalcetrapib after Pfizer’s failure because of experiments showing the two drugs don’t work the same way and don’t share the same toxicity, Alexander Klauser, a spokesman for Roche, said in an e-mail.
“Step one with your drug is to make sure it doesn’t kill anyone, and with this class, given the experience with torcetrapib, safety’s been a real concern,” said Jack Scannell, a London-based analyst for Sanford C. Bernstein Ltd.
No comments:
Post a Comment